Cargando…

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains most...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kachmazov, Andrei, Bolotina, Larisa, Kornietskaya, Anna, Kuznetsova, Olesya, Ivanov, Maxim, Fedenko, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/ https://www.ncbi.nlm.nih.gov/pubmed/36119518 http://dx.doi.org/10.3389/fonc.2022.953908

Ejemplares similares

Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report
por: Kornietskaya, Anna, et al.
Publicado: (2022)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Postoperative Chemotherapy After Surgical Resection of Metachronous Metastases of Colorectal Cancer: A Systematic Review
por: Evdokimova, Sevindzh, et al.
Publicado: (2023)

Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation
por: Wu, Wei, et al.
Publicado: (2022)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
por: Hu, Zhe-Yu, et al.
Publicado: (2020)

PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma
por: Ge, Ouyang, et al.
Publicado: (2021)

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
por: Baldwin, Paige, et al.
Publicado: (2019)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management
por: Wu, Shijie, et al.
Publicado: (2020)

PALB2 as a factor to predict the prognosis of patients with skull base chordoma
por: Xiong, Yujia, et al.
Publicado: (2022)

9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
por: Poloznikov, Andrey, et al.
Publicado: (2021)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer
por: Wang, Tao, et al.
Publicado: (2022)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

Gastrointestinal Goblet Cell Adenocarcinomas Harbor Distinctive Clinicopathological, Immune, and Genomic Landscape
por: Lin, Dong-Liang, et al.
Publicado: (2021)

Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction
por: Caleca, Laura, et al.
Publicado: (2018)

Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients
por: Zhang, Jiexia, et al.
Publicado: (2022)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis
por: Tang, Tang, et al.
Publicado: (2020)

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
por: Rodon Ahnert, J., et al.
Publicado: (2023)

EARS2 significantly coexpresses with PALB2 in breast and pancreatic cancer
por: Lehrer, Steven, et al.
Publicado: (2022)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
por: Takeuchi, Shoko, et al.
Publicado: (2018)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
por: Li, Jian, et al.
Publicado: (2022)

Application of artificial intelligence to pancreatic adenocarcinoma
por: Chen, Xi, et al.
Publicado: (2022)

Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
por: Li, Jie, et al.
Publicado: (2020)

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
por: Wang, Junhui, et al.
Publicado: (2023)

Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
por: Meng, Fan, et al.
Publicado: (2021)

Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report
por: Abe, Kodai, et al.
Publicado: (2021)

Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie
por: De Angelis, Carmine, et al.
Publicado: (2021)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review
por: Xu, Xiaohu, et al.
Publicado: (2022)

Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN
por: Guo, Xi, et al.
Publicado: (2022)

Computational Image Analysis Identifies Histopathological Image Features Associated With Somatic Mutations and Patient Survival in Gastric Adenocarcinoma
por: Cheng, Jun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i020p4vuip4kn5og5mfhmahro4